- Home
- IONS
as 10-06-2025 10:31am EST
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 6.8B | IPO Year: | 1991 |
| Target Price: | $72.83 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.95 - $69.25 | Next Earning Date: | 11-05-2025 |
| Revenue: | $944,050,000 | Revenue Growth: | 16.05% |
| Revenue Growth (this year): | 24.01% | Revenue Growth (next year): | 4.06% |
Stock Insider Trading Activity of Ionis Pharmaceuticals Inc. (IONS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Baroldi Joseph | IONS | EVP, Chief Business Officer | Oct 2 '25 | Sell | $68.01 | 15,000 | $1,020,210.00 | 31,926 | |
| Swayze Eric | IONS | EVP Research | Oct 2 '25 | Sell | $66.23 | 12,972 | $859,082.37 | 37,302 | |
| O'NEIL PATRICK R. | IONS | EVP CLO & General Counsel | Oct 2 '25 | Sell | $67.69 | 64,664 | $4,377,054.43 | 57,130 | |
| Swayze Eric | IONS | EVP Research | Oct 1 '25 | Sell | $66.09 | 14,142 | $934,661.75 | 37,302 | |
| WENDER JOSEPH H | IONS | Director | Oct 1 '25 | Sell | $65.50 | 16,800 | $1,100,384.88 | 92,035 | |
| Geary Richard S | IONS | EVP, Chief Development Officer | Sep 30 '25 | Sell | $65.24 | 57,900 | $3,777,668.13 | 79,657 | |
| O'NEIL PATRICK R. | IONS | EVP CLO & General Counsel | Sep 30 '25 | Sell | $64.68 | 14,827 | $958,976.26 | 57,130 | |
| HOUGEN ELIZABETH L | IONS | EVP, Finance & CFO | Sep 30 '25 | Sell | $65.26 | 49,800 | $3,249,733.86 | 110,500 | |
| O'NEIL PATRICK R. | IONS | EVP CLO & General Counsel | Sep 29 '25 | Sell | $64.54 | 10,473 | $675,945.22 | 57,130 | |
| O'NEIL PATRICK R. | IONS | EVP CLO & General Counsel | Sep 12 '25 | Sell | $64.58 | 1,700 | $109,787.19 | 57,130 |
Latest Ionis Pharmaceuticals Inc. News
IONS Breaking Stock News: Dive into IONS Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Ionis Pharmaceuticals Insider Sold Shares Worth $1,100,385, According to a Recent SEC Filing
MT Newswires
3 days ago
Ionis Pharmaceuticals Insider Sold Shares Worth $1,793,744, According to a Recent SEC Filing
MT Newswires
3 days ago
Ionis Pharmaceuticals Insider Sold Shares Worth $4,377,054, According to a Recent SEC Filing
MT Newswires
3 days ago
Ionis Pharmaceuticals Insider Sold Shares Worth $1,020,210, According to a Recent SEC Filing
Insider Monkey
4 days ago
Ionis (IONS) Price Target Hiked Following Positive Zilganersen Trial Results
Business Wire
a month ago
Ionis to host investors and analysts for Innovation Day 2025
Simply Wall St.
a month ago
Ionis Pharmaceuticals (IONS) Is Up 43.6% After Positive Phase 3 Olezarsen Results in Severe Hypertriglyceridemia – Has the Bull Case Changed?
MT Newswires
a month ago
Ionis Pharmaceuticals Insider Sold Shares Worth $5,396,843, According to a Recent SEC Filing
Compare IONS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IONS Ionis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.